Exchange: NASDAQ·Updated 04:10 PM EDT
PRTA logo

PRTAProthena Corporation plc

$9.69
$0.11
(1.15%)
Today
Closed $9.69
$0.00
(0.00%)
After Hours
EarningsAug 3
Mkt Cap$507.3M
Vol462,875.00
News
all
press releases
SRPT or PRTA: Which Is the Better Value Stock Right Now?
SRPT vs. PRTA: Which Stock Is the Better Value Option?
Zacks
News Placeholder
More News
News Placeholder
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks
News Placeholder
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
Zacks
News Placeholder
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2026 and provided business highlights. In the quarter we...
Business Wire
News Placeholder
Prothena to Report First Quarter 2026 Financial Results on May 7
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
Business Wire
News Placeholder
Prothena (NASDAQ:PRTA) Shares Up 5.9% - Time to Buy?
Prothena (NASDAQ:PRTA) Trading Up 5.9% - Here's What Happened...
MarketBeat
News Placeholder
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter...
Business Wire
News Placeholder
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts
Shares of Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) have earned a consensus rating of "Hold" from the eleven analysts that are covering the company, Marketbeat.com reports. Two...
MarketBeat
News Placeholder
Prothena (NASDAQ:PRTA) Share Price Passes Above 200-Day Moving Average - Time to Sell?
Prothena (NASDAQ:PRTA) Share Price Passes Above 200 Day Moving Average - Here's Why...
MarketBeat
News Placeholder
Prothena Announces Leadership Team Updates
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.